­Table 1. Gender-related differences in the prevalence of and relevant molecules to vascular calcification

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Authors | Country | Time | CKD stages | Sample size | Findings | Data | Calcification assessment method | Ref |
| Ahmed *et al.* | United States | 2001 | 5D | 10 | Female common | Male vs. female, 10% vs. 90%, *p* < 0.02 | Calciphylaxis on skin biopsy | (1) |
| Alayoud *et al* | France | 2020 | 5D (HD) | 28 | Male more likely to progress | Progression vs. stable, male 83.3% vs. 36.4%, *p* = 0.02 | Coronary artery calcification (Agatston score) | (2) |
| Al-Rifai *et al.* | Lebanon | 2011 | 5D (HD) | 43 | Neutral | No association between VC and gender | Hand X-rays | (3) |
| Asci *et al.* | Turkey | 2010 | 5D (HD) | 207 | Male common and more severe | Score >0 vs. 0, male 57% vs. 41%, *p* = 0.05  Score >400 vs. 101-400 vs. 1-100, male 61% vs. 72% vs. 38%, *p* = 0.005 | Coronary artery calcification (Agatston score) | (4) |
| Avramovski et al. | Macedonia | 2019 | 5D | 112 | Neutral | No association between VC and gender | Lumbar spine lateral radiography | (5) |
| Bae *et al.* | Korea (multicenter) | 2016 | 5D (HD) | 423 | Male common and more severe | Male vs. female, positive CAC 69.37% vs. 53.95%, *p* = 0.001  Male vs. female, CAC scores 44.1 vs. 5.15, *p* = 0.0041 | Coronary artery calcification (Agatston score) | (6) |
| Ballotta *et al.* | Italy | 2004 | 5D | 143 | Neutral | With vs. without, male 78% vs. 74%, *p* = 0.59 | Calcified vessels determined intra-operatively | (7) |
| Bellasi *et al.* | United States | 2012 | 5D (HD) | 141 | Neutral | Cardiovascular calcification index score 8–11 vs. 5–7 vs. 3–4 vs. 0–2, male 62% vs. 39% vs. 52% vs. 49%, *p* = 0.57 | Lumbar spine lateral radiography (Kauppila score) and echocardiography-derived valve calcification | (8) |
| Bundy *et al.* | United States (CRIC) | 2019 | 2-4 | 3404 | Neutral | Quartile 1 (severe) vs. 2 vs. 3 vs. 4, female 47% vs. 48% vs. 44% vs. 41%, *p* > 0.05 | T50 (propensity of calcification) | (9) |
| Chandra *et al.* | India | 2020 | 5D | 90 | Neutral | With vs. without, male 67.5% vs. 62%, *p* = 0.59 | Coronary artery calcification (Agatston score) and thoracic aortic calcification by computed tomography | (10) |
| Chang *et al* | South Korea | 2012 | 5D (HD) | 289 | Neutral | Severe vs. modest calcification, male 41.8% vs. 44.7%, *p* = 0.066 | Lumbar spine lateral radiography | (11) |
| Chao *et al.* | Taiwan | 2020 | 5D (HD) | 96 | Neutral | With vs. without, male 47% vs. 43%, *p* = 0.711 | Aortic arch calcification on chest radiography | (12) |
| Chao *et al.* | Taiwan | 2017 | 5D (HD) | 88 | Neutral | With vs. without, male 59% vs. 66%, *p* = 0.54 | Aortic arch calcification on chest radiography | (13) |
| Charitaki *et al.* | United Kingdom | 2014 | 5D (HD) | 303 | Male more severe | Correlation with female, r = -0.124, *p* = 0.031 | Pulse wave velocity | (14) |
| Chen *et al* | Sweden | 2017 | 5D, 5T | 240 | Neutral | Score > 100 vs. ≤ 100, male 68% vs. 57%, *p* = 0.052 | Coronary artery calcification (Agatston score) | (15) |
| Chen *et al.* | United States | 2017 | 1-4 | 1541 | Male more severe | Scores >100 vs. 0-100 vs. 0, male 65.2% vs. 54.3% vs. 41.7%, *p* < 0.001 | Coronary artery calcification (Agatston score) | (16) |
| Chiu *et al* | United States | 2010 | Proteinuric (1-5) | 225 | Neutral | Group 4 (severe) vs. 3 vs. 2 vs. 1, male 61% vs. 64% vs. 47% vs. 45%, *p* = 0.09 | Coronary artery calcification (Agatston score) | (17) |
| Choi *et al.* | Korea | 2019 | 5D (HD) | 97 | Male more likely to progresses | Progression vs. stable, male 50.9% vs. 29.5%, *p* = 0.033 | Lateral lumbar radiography (Kauppila score) | (18) |
| Chue *et al.* | United Kingdom | 2012 | 3 | 120 | Male common | Male vs. Female, 67% vs. 43%, *p* = 0.01 | Lumbar spine lateral radiography | (19) |
| Claes *et al.* | Belgium | 2013 | 5T | 115 | Neutral | No differences in scores between genders | Lateral lumbar radiography (Kauppila score) | (20) |
| Coen *et al.* | Italy | 2006 | 5D (HD) | 132 | Male more severe | Score >1000 vs. 400-1000 vs. 1-400 vs. 0-1, male 74.6% vs. 61.9% vs. 61.3% vs. 38.4%  Scores correlated with male gender (*p* < 0.05) | Coronary artery calcification (Agatston score) | (21) |
| Coll *et al.* | Spain | 2010 | 5D | 232 | Male more common | With vs. without linear calcification, male 65% vs. 41%, *p* = 0.01 | Vascular ultrasound for carotid, femoral, or brachial arteries | (22) |
| Craver *et al* | Spain | 2013 | 3-4 | 178 | Male more severe | Scores >5 vs. 1-5 vs. 0, male 83% vs. 80% vs. 70%, *p* = 0.017 | Lateral lumbar radiography (Kauppila score) | (23) |
| Davis *et al.* | United States | 2016 | 5T | 131 | Neutral | Regression between scores and male gender, r = -0.16~0.051, *p* > 0.05 | Iliac arteries calcification by computed tomography | (24) |
| DeLoach *et al.* | United States | 2009 | 5T | 112 | Neutral | With vs. without, male 68.4% vs. 58.1%, *p* = 0.29 | Coronary artery calcification (Agatston score) and aortic calcification by computed tomography | (25) |
| Di Iorio *et al.* | Italy | 2006 | 4-5, 5D | 44 | Male more severe | Scores >400 vs.<400, male 75% vs. 42%, *p* = 0.05 | Coronary artery calcification (Agatston score) | (26) |
| Disthabanchong *et al.* | Thailand | 2018 | 2-5D, 5T | 419 | Female more severe (subgroup) | AAC score > 6 vs. ≤ 6 in CKD stage 2 -5, male 44.4% vs. 62.6, p < 0.05  In male with stage 5D, 50% vs. 50.5% (P > 0.05)  In male with stage 5T, 67.9% vs. 58.5% (p > 0.05) | Lateral lumbar radiography (Kauppila score) | (27) |
| El Amrani *et al.* | Morocco | 2015 | 5D (HD) | 49 | More male with CAC | With vs. without, male 64.7% vs. 26,6 %, *p* = 0.014 | Coronary artery calcification (Agatston score) | (28) |
| Etta *et al.* | India | 2017 | 4-5 | 95 | Neutral | With vs. without, 70% vs. 71.8%, p = 0.58 | Lumbar spine lateral radiography | (29) |
| Fabbian *et al.* | Italy | 2005 | 5D (HD) | 132 | Neutral | No difference between genders | Aortic arch calcification on chest radiography | (30) |
| Fayed *et al.* | Egypt | 2019 | 5 | 172 | Neutral | Intimal vs. medial vs. none, male 37.9% vs. 64.9% vs. 58.1% | Arterial wall calcification based on intraoperative arterial biopsy | (31) |
| Gunen Yilmaz *et al.* | Turkey | 2019 | 5D (HD) | 60 | Neutral | With vs. without, male 53.3% vs. 53.3%, p = 0.25 | Carotid artery calcification on plain radiography and ultrasound | (32) |
| Harada *et al* | Brazil | 2014 | 2-5 | 117 | Male more severe | Score >0 vs. score =0, male 78.7% vs. 42.9%, *p* < 0.001 | Coronary artery calcification (Agatston score) | (33) |
| He *et al.* | China | 2018 | 5D (HD) | 150 | Neutral | With vs. without, male 61.1% vs. 76.2%, *p* = 0.099 | Lateral lumbar radiography (Kauppila score) | (34) |
| He *et al.* | United States | 2012 | 2-4 | 2018 | Male more severe | Score >100 vs. 0-100 vs. 0, male 63.6% vs. 53.3% vs. 41.9%, *p* < 0.0001 | Coronary artery calcification (Agatston score) | (35) |
| Hou *et al* | Taiwan | 2019 | 5D (HD) | 120 | Neutral | High vs. low, male 52.8% vs. 47.8%, *p* = 0.851 | Pulse wave velocity | (36) |
| Humoud *et al.* | Kuwait | 2005 | 5D | 129 | Neutral | With vs. without, male 58.8% vs. 45.3%, *p* = 0.175 | Hand X-rays | (37) |
| Jankovic *et al* | Serbia | 2017 | 5D (HD) | 90 | Male common | With vs. without, male 66.1% vs. 35.3%, *p* = 0.008 | Forearm AVF plain radiography | (38) |
| Jankovic *et al.* | Serbia | 2015 | 5D (HD) | 90 | Male gender | Scores 8-11 vs. 4-7 vs. 0-3, 76.7% vs. 50% vs. 38.9%, *p* = 0.008 | Plain radiography of pelvis and hands (Adragao score) + forearm AVF plain radiography | (39) |
| Jansson *et al* | Sweden | 2019 | 3-4 | 84 | Neutral | With vs. without, male 79% vs. 67%, *p* = 0.351 | Abdominal aortic calcification on computed tomography | (40) |
| Jean *et al* | France | 2016 | 5D (HD) | 227 | Neutral | Group 3 (severe) vs. 2 vs. 1, male 59.7% vs. 55.6% vs. 59.2%, *p* > 0.05 | Lumbar spine lateral radiography | (41) |
| Jean *et al* | France | 2009 | 5D (HD) | 161 | Male more severe | High score (3) vs. no (score 0), male 77% vs. 45%, *p* < 0.05 | Multi-site plain radiography involving pelvis, lumbar, knee, right hand, right arm, chest, skull, and orthopantomogram | (42) |
| Jean *et al.* | France | 2012 | 5D (HD) | 85 | Neutral | Progression vs. stable, male 56% vs. 48%, *p* > 0.05 | Multi-site plain radiography involving pelvis, lumbar, knee, right hand, right arm, chest, skull, and orthopantomogram | (43) |
| Jiménez Villodres *et al.* | Spain | 2018 | 3 | 139 | Male more common | With and without abdominal aortic calcification, male 80% vs. 63%, *p* < 0.05  With and without KI, male 69% vs. 72%, *p* > 0.05 | Lateral lumbar radiography (Kauppila score) and abdominal aortic calcification on computed tomography | (44) |
| Kahn *et al* | Austria | 2017 | 5T | 205 | Male more severe, segment-specific | Aorta: male vs. female, 2.0 vs. 1.5, *p* = 0.511  Right common iliac artery: male vs. female, 1.0 vs. 1.0, *p* = 0.139  Total iliac artery: male vs. female, 1.00 vs. 0.50, *p* = 0.003  External iliac artery: male vs. female, 1.0 vs. 0.0, *p* <0.001 | Pelvic computed tomography | (45) |
| Keyzer *et al.* | Netherlands | 2015 | 5T | 699 | Neutral | Tertile 1 (severe) vs. 2 vs. 3, male 58% vs. 55% vs. 57%, *p* = 0.73 | T50 (propensity of calcification) | (46) |
| Kim *et al.* | Korea | 2019 | 5D | 47 | Neutral | With vs. without, male 83.3% vs. 69%, *p* = 0.324 | AVF anastomotic segment medial calcification by ultrasound | (47) |
| Kim *et al.* | Korea | 2011 | 5D | 184 | Neutral | Progression vs. stable, 44% vs. 41%, *p* = 0.657 | Aortic arch calcification on chest radiography | (48) |
| Kimura *et al.* | Japan | 1999 | 5D (HD) | 137 | Male more common early during lifetime | With calcification during age 40s, male vs. female 4.0% vs. 3.7%, *p* < 0.01 | Abdominal aortic calcification by computed tomography | (49) |
| Komatsu *et al* | Japan | 2014 | 5D (HD) | 301 | Female common | Grade 2+3 vs. 1 vs. no calcification, male 58.7% vs. 56.3% vs. 77.8%, *p* = 0.0009 | Aortic arch calcification on chest radiography | (50) |
| Lee e*t al* | Taiwan | 2014 | 5D (HD) | 712 | Neutral | Group 3 (severe) vs. 2 vs. 1 vs. none, male 38.1% vs. 42.2% vs. 45.7% vs. 43.8%, *p* = 0.606 | Aortic arch calcification on chest radiography | (51) |
| Lee *et al.* | Taiwan | 2019 | 5D (HD) | 61 | Neutral | With vs. without, male 52% vs. 37%, p = 0.240 | Lateral lumbar radiography (Kauppila score) | (52) |
| Lee *et al.* | Korea | 2006 | 2-5 | 1078 | Male more common | With vs. without, male 73.7% vs. 54.4%, *p* < 0.001 | Coronary artery calcification (Agatston score) | (53) |
| Lioufas *et al.* | Multicenter (IMPROVE-CKD) | 2020 | 3b-4 | 278 | Male more common | With vs. without, male 73% vs. 55%, *p* = 0.02 | Abdominal aortic calcification by computed tomography | (54) |
| Liu *et al.* | China | 2016 | 5D | 41 | Neutral | With vs. without, male 66.67% vs. 59.38%, *p* = 0.993 | Immunohistochemical analysis of radial arterial calcium deposition | (55) |
| Lockhart *et al.* | United States | 2004 | 5D (HD) | 32 | Neutral | Scores high vs. low, male 67% vs. 42%, *p* = 0.28 | Abdominal aorta, common iliac, external iliac and common  femoral artery calcification on computed tomography | (56) |
| London *et al.* | France | 2013 | 5D (HD) | 155 | Neutral | With vs. without, male-to-female ratio 1.38 vs. 1.44, *p* > 0.05 | Common carotid artery calcification by ultrasound | (57) |
| Maharem *et al* | Egypt | 2013 | 5, 5D, 5T | 73 | Neutral | VC presence vs. absence, male 57.9% vs. 31.6%, *p* = 0.056 | Pelvic and hand plain radiography | (58) |
| Mazzaferro *et al.* | Italy | 2007 | 5D, 5T | 100 | Male more severe | Male dialysis vs. male transplant vs. female dialysis vs. female transplant, 1944 vs. 945 vs. 157 vs. 35, *p* < 0.02 | Coronary artery calcification (Agatston score) | (59) |
| Merjanian *et al.* | United States | 2003 | 3-5 | 32 | Male more severe | Male vs female, 619 vs. 232, *p* < 0.001 | Coronary artery calcification (Agatston score) | (60) |
| Miyatake *et al.* | Japan | 2020 | 5T | 50 | Neutral | Male vs. female 1.72 vs. 0.00, *p* > 0.05 | Abdominal aortic calcification by computed tomography | (61) |
| Mizuiri *et al.* | Japan | 2018 | 2-5 | 145 | Neutral | Coronary calcification quartile 4 vs. 3 vs. 2 vs. 1, male 62.9% vs. 64.9% vs. 54.1% vs. 63.9%, *p* > 0.05  Iliac calcification quartile 4 vs. 3 vs. 2 vs. 4, male 58.3% vs. 65.8% vs. 68.6% vs. 52.8%, *p* > 0.05 | Coronary artery calcification (Agatston score) and common iliac artery calcification by computed tomography | (62) |
| Morena *et al* | France | 2009 | 1-5 | 133 | Male common | Severe vs. minor, 73.6% vs. 36.1%, *p* < 0.0001 | Coronary artery calcification (Agatston score) | (63) |
| Munguia *et al.* | Spain | 2015 | 5T | 119 | Neutral | With vs. without, 70% vs. 62.3%, *p* = 0.384 | Lateral lumbar radiography (Kauppila score) | (64) |
| Nitta *et al* | Japan | 2018 | 5D (HD) | 216 | Female more severe | Group 3 (severe) vs. 2 vs. no calcification, female 47.5% vs. 40.9% vs. 23.1%, *p* < 0.0001 | Aortic arch calcification on chest radiography | (65) |
| Niu *et al.* | China | 2019 | 5D (PD) | 150 | Neutral | With vs. without, male 51.65% vs. 49.15%, *p* = 0.765 | Plain films of lateral abdomen, frontal pelvic, and both hands for abdominal aorta, iliac, femoral, radial, and digital arteries | (66) |
| Niu *et al.* | China | 2019 | 5D (HD) | 56 | Neutral | Progression score >500 vs. 100–500 vs. <100, male 70.7% vs. 73.7% vs. 59.3%, *p* = 0.572 | Coronary artery calcification (Agatston score) | (67) |
| Okamoto *et al* | Japan | 2018 | 5D (HD) | 184 | Male more likely to worsen | Annual progression rapid vs. slow, male 53% vs. 27%, *p* = 0.008 | Abdominal aorta calcification on computed tomography | (68) |
| Petrovic *et al.* | Serbia | 2020 | 5D (HD) | 80 | Neutral | PWV >8.8 vs. ≤8.8 m/s, male 20% vs. 14%, *p* = 0.119 | Pulse wave velocity | (69) |
| Qureshi *et al* | Sweden | 2015 | 5T | 89 | Male more severe | Moderate-severe vs. non-minimal, male 76% vs. 54%, *p* = 0.04 | Biopsy-verified calcification in epigastric arteries | (70) |
| Raggi *et al.* | United States | 2011 | 5D (HD) | 144 | Neutral | Number of calcified valves 2 vs. 1 vs. 0, male 61.1% vs. 44.7% vs. 45.9%, *p* = 0.19 | Calcified cardiac valves on computed tomography | (71) |
| Renaud *et al.* | France | 1988 | 5D (HD) | 24 | Male more likely to worsen | Correlation coefficient for male vs. annual calcification increase = 1.97, *p* < 0.01 | Lumbosacral radiography for linear calcifications involving the abdominal aorta, iliac and femoral arteries | (72) |
| Ribeiro *et al.* | Portugal | 1998 | 5D (HD) | 92 | Neutral | No difference between genders | Calcified cardiac valves on computed tomography | (73) |
| Roca-Tey *et al.* | Spain | 2009 | 5D (HD) | 45 | Neutral | With vs. without, male 81.5% vs. 55.6%, *p* = 0.09 | Arteriovenous fistula calcification on computed tomography | (74) |
| Schlieper *et al* | Serbia | 2008 | 5D (HD) | 212 | Male common | With vs. without, male 78% vs. 47%, *p* < 0.0001 | Vascular access calcification on plain radiography | (75) |
| Shu *et al* | Taiwan | 2012 | 5T | 99 | Male more severe | Group 5 (severe) vs. 4 vs. 3 vs. 2 vs. 1, male 66.7% vs. 53.3% vs. 63.6% vs. 65.0 vs. 29.3%, *p* = 0.027 | Coronary artery calcification (Agatston score) | (76) |
| Sigrist *et al.* | United Kingdom | 2006 | 4-5D | 134 | Male more severe | Tertiles 3 vs. 2 vs. 1, male 81% vs. 71% vs. 46%, *p* < 0.001 | Superficial femoral artery calcification by computed tomography | (77) |
| Strózecki *et al.* | Poland | 2005 | 5D (HD) | 65 | Neutral | With vs. without, male 43.8% vs. 48.5%, *p* > 0.05 | Calcified cardiac valves on ultrasound | (78) |
| Tangvoraphonkchai *et al.* | United States | 2019 | 5D (PD) | 24 | Male gender (%) | Stable PWV vs. increased PWV, male 33% vs. 75% | Pulse wave velocity | (79) |
| Tomiyama *et al.* | Brazil | 2010 | 2-4 | 50 | Male more common | With vs. without, male 79% vs. 47%, *p* = 0.02 | Coronary artery calcification (Agatston score) | (80) |
| Turan *et al* | Turkey | 2016 | 5D (HD) | 224 | Male more severe | Group 4 (severe) vs. 3. vs. 2 vs. no calcification, male 56% vs. 59% vs. 38% vs. 41%, *p* = 0.003 | Coronary artery calcification (Agatston score) | (81) |
| Wang *et al.* | Hong Kong | 2014 | 3-5 | 300 | Male more severe | Scores ≥400 vs. 100–399 vs. 1–99 vs. 0, male 77.3% vs. 56.9% vs. 57.5% vs. 38.7%, *p* < 0.001 | Coronary artery calcification (Agatston score) | (82) |
| Wang *et al.* | Hong Kong | 2003 | 5D (PD) | 192 | Neutral | With vs. without, male 50.0% vs. 51.5%, *p* = 0.842 | Calcified cardiac valves on ultrasound | (83) |
| Wu *et al.* | Taiwan | 2017 | 5D (PD) | 190 | Neutral | Grade 3 vs. 2 vs. 1 vs. 0, male 37.0% vs. 58.3% vs. 40.4% vs. 43.8%, *p* = 0.293 | Aortic arch calcification on chest radiography | (84) |
| Yoshikawa *et al.* | Japan | 2013 | 5D (HD) | 134 | Male more common | β = -0.20, *p* = 0.008 | Abdominal aorta calcification on computed tomography | (85) |
| Zhou *et al.* | Sweden | 2018 | 1-5 | 151 | Male more common | Male vs. female: 76% vs. 69%, *p* < 0.05 | Lateral lumbar radiography (Kauppila score) | (86) |
| Abd Alamir *et al.* | United States | 2015 | 2-3 | 2070 | Neutral | With vs. without, male 49.6% vs. 54.5%, *p* = 0.1 | Mitral annular calcification by coronary computed tomography | (87) |
| Adragao *et al.* | Portugal | 2004 | 5D (HD) | 123 | Male more severe | Score ≥3 vs. <3, female 22% vs. 58%, *p* < 0.001 | Plain radiography of pelvis and hands (Adragao score) | (88) |
| Bundy *et al* | United States | 2019 | 2-4 | 1274 | Neutral | Quartiles 4 vs. 3 vs. 2 vs. 1, female 46% vs. 45% vs. 49% vs. 47% | T50 (propensity of calcification) | (89) |
| Chae *et al.* | Korea | 2018 | 1-5 | 1832 | Neutral | Quartile 4 vs. 3 vs. 2 vs. 1, female 38.1% vs. 37.0% vs. 41.3% vs. 44.3%, *p* = 0.101 | Pulse wave velocity | (90) |
| Claes *et al.* | Belgium | 2013 | 5T | 115 | Neutral | Prevalence male vs. female, 61% vs. 50.7%, *p* = 0.16 | Lateral lumbar radiography (Kauppila score) | (20) |
| Dai *et al* | Sweden | 2020 | 5 | 152 | Male more severe | Moderate to extensive vs. no to minimal, male 81% vs. 56%, *p* = 0.002 | Histopathology of epigastric artery calcification | (91) |
| Floege *et al.* | Multicenter | 2010 | 5D (HD) | 360 | Neutral | Score ≥ 1000 vs. 400-999 vs. 30-399, 65% vs. 55% vs. 51% | Coronary artery calcification (Agatston score) | (92) |
| Gelev *et al.* | Macedonia | 2008 | 5D (HD) | 150 | Male more common, especially intimal | VC prevalence: male vs. female, 87.9% vs. 61.0%, *p* < 0.03  Intimal VC: male vs. female, 53.8% vs. 32.2%, *p* < 0.02  Medial VC: male vs. female, 34.1% vs. 28.8%, *p* > 0.05 | Pelvic antero-posterior radiography | (93) |
| Kestenbaum *et al.* | United States | 2009 | 3-5 | 562 | Male more common | With vs. without, male 45% vs. 29%, *p* < 0.001 | Coronary artery calcification (Agatston score) | (94) |
| Maia *et al.* | Brazil | 2018 | 5D (HD) | 309 | Female more common | With vs. without, male 44.9% vs. 60.8%, *p* = 0.039 | Carotid artery calcification on panoramic radiographs | (95) |
| Maréchal *et al.* | Belgium | 2012 | 5T | 197 | Male more likely to worsen | Rapid progressor vs. slow progressor vs. non-progressor, male 66% vs. 65% bs. 45%, *p* = 0.02 | Coronary artery calcification (Agatston score) and thoracic artery calcification by computed tomography | (96) |
| Moldovan *et al.* | Romania | 2010 | 5D (HD) | 81 | Neutral | With vs. without, male 63.2% vs. 41.7%, *p* = 0.44 | Plain radiography of pelvis and hands (Adragao score) | (97) |
| Muntner *et al.* | United States | 2006 | 5D (HD) | 148 | Neutral | Score ≥ 1000 vs. 400-999 vs. 100-399 vs. 1-99 vs. 0, female 45.5% vs. 46.4% vs. 50% vs. 61.8% vs. 50%, *p* = 0.184 | Coronary artery calcification (Agatston score) | (98) |
| Porter *et al.* | United Kingdom | 2007 | 3-4 | 112 | Male more common | In non-diabetic group, VC prevalence in male vs. female, 60% vs. 26%, *p* = 0.003 | Coronary artery calcification (Agatston score) | (99) |
| Wang *et al* | China | 2019 | 5D (HD) | 108 | Neutral | Severe vs. mild vs. none, male 30% vs. 23.1% vs. 43.8%, *p* = 0.08 | Abdominal aortic calcification (Kauppila score) | (100) |
| Wang *et al.* | China | 2014 | 5D (HD) | 77 | Male more common | Score >400 vs. 11-400 vs. <10, male 67.8% vs. 53.8% vs. 26.1%, *p* < 0.001 | Coronary artery calcification (Agatston score) | (101) |
| Stefan *et al.* | Romania | 2014 | 3-4 | 77 | Female more severe | AAC score ≤ 5 vs. > 5, male/female 25/15 vs. 13/24, p = 0.01 | AAC on lateral lumbar X-ray (Kauppila score) | (102) |
| Tomiyama *et al.* | Brazil | 2006 | 2-4 | 96 | Neutral | CACS > 0 vs. 0, male 70% vs. 60%, p = 0.29 | Coronary calcification assessed on computed tomography | (103) |
| Ammirati *et al.* | Brazil | 2006 | 5D (PD) | 49 | Neutral | CACS > 10 vs. < 10, female 44% vs. 70%, p = 0.33 | Coronary artery calcification on computed tomography | (104) |
| Chavent *et al.* | France | 2017 | 5T | 100 | Neutral | 1st vs. 2nd vs. 3rd vs. 4th quartile, male 60% vs. 52% vs. 76% vs. 80%, p = 0.08 | Aortic and iliac calcification score on abdominal computed tomography (Agatston score) | (105) |
| Tian *et al.* | China | 2016 | 5D (PD) | 194 | Neutral | With vs. without cardiac valve calcification, male 51.6% vs. 43.2%, p = 0.27 | Cardiac valve calcification on echocardiography | (106) |
| Ulutas *et al.* | Turkey | 2017 | 5D (HD) | 93 | Neutral | With vs. without VC, male 24.7% vs. 22.6%, p = 0.480  **No vs. one area vs. two area, male 22.6% vs. 7.5% vs. 17.2, p = 0.032** | Vascular calcification on anteroposterior wrist radiographs | (107) |
| Turkmen *et al.* | Turkey | 2011 | 5D (HD) | 78 | Neutral | CACS < vs. ≥ 10, male/female 8/17 vs. 30/23, p > 0.05 | Coronary artery calcification on computed tomography (Agatston score) | (108) |
| Takayama *et al.* | Japan | 2015 | 3-5 | 126 | Neutral | AAC tertile 1 vs. 2 vs. 3, male 71 % vs. 74% vs. 71%, p = 0.96 | AAC on abdominal computed tomography | (109) |
| Tsukada *et al.* | Japan | 2019 | 5D (PD) | 30 | Neutral | Progressors vs. nonprogressors, male 54.5% vs. 85.7%, p > 0.05 | Aortic arch calcification on chest radiography | (110) |
| El Baz *et al.* | Egypt | 2017 | 5D (HD) | 60 | Neutral | With vs. without, male/female 13/17 vs. 15/15, p > 0.05 | AAC on lateral abdominal X-rays | (111) |
| Moldovan *et al.* | Romania | 2013 | 5D (HD) | 88 | Neutral | With vs. without, male 52.94% vs. 50%, p = 0.48 | Carotid artery calcification on ultrasound | (112) |
| Lee *et al.* | Taiwan | 2016 | 5D (HD) | 227 | Neutral | Severe vs. Moderate vs. Mild vs. No, male 55% vs. 44% vs. 49% vs. 35%, p > 0.05 | AAC on lateral lumbar radiography (Kauppila score) | (113) |

*AAC, abdominal aortic calcification; CKD, chronic kidney disease; HD, hemodialysis; LAD, left anterior descending; PD, peritoneal dialysis; VC, vascular calcification*

Table 2. Gender-related risk of vascular calcification in existing studies

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Authors | Country | Time | CKD stages | Sample size | Findings | Results | Calcification assessment method | Ref |
| Abd Alamir *et al.* | United States | 2015 | 2-3 | 2070 | Neutral | Female OR 1.21 (0.94–1.56) | Mitral annular calcification by coronary computed tomography | (87) |
| Adragao *et al.* | Portugal | 2004 | 5D (HD) | 123 | Male at risk for severe disease | Score ≥ 3 OR 7.47 (2.9–19.1) | Plain radiography of pelvis and hands (Adragao score) | (88) |
| Bellasi *et al* | United States | 2008 | 5D | 142 | Male at risk (subgroup) | For coronary artery calcification, male β = 735.82, p = 0.0366  For thoracic aorta, gender *p* > 0.05 | Coronary artery calcification (Agatston score) and thoracic aorta calcification | (114) |
| Budoff *et al.* | United States | 2011 | 2-3A | 1908 | Male at risk | Female OR 0.43 (0.35-0.53) | Coronary artery calcification (Agatston score) | (115) |
| Cai *et al.* | China | 2015 | 5D (HD) | 129 | Neutral | Male OR 0.549 (0.113–2.661), *p* = 0.456 | Lateral lumbar radiography | (116) |
| Chen *et al.* | Sweden | 2017 | 5D, 5T | 240 | Male at risk | β = 0.35, *p* = 0.008 | Coronary artery calcification (Agatston score) | (15) |
| Chiu *et al.* | United States | 2010 | Proteinuric (1-5) | 225 | Male at risk | Male with significantly higher probability of more severe VC (*p* = 0.01) | Coronary artery calcification (Agatston score) | (17) |
| Chue *et al* | United Kingdom | 2012 | 3 | 120 | Male at risk | Female β = -0.34 (-13.45– -4.48) | Lumbar spine lateral radiography | (19) |
| Coll *et al.* | Spain | 2010 | 5D | 232 | Neutral | Male OR 1.57 (0.69–3.55), *p* = 0.27 | Vascular ultrasound for carotid, femoral, or brachial arteries | (22) |
| Craver *et al.* | Spain | 2013 | 3-4 | 178 | Male at risk | For AAC severity, male β = 1.237 (0.058-2.417), *p* = 0.04  For severe AAC, in all patients, male OR 4.218 (1.403-14.207), p = 0.014  For severe AAC, in eGFR < 30: OR 4.167 (1.050-20.178) | Abdominal aortic calcification (Kauppila score) | (23) |
| Dai *et al* | Sweden | 2020 | 5 | 152 | Male at risk | Male OR 6.67 (2.53–17.58) | Histopathology of epigastric artery calcification | (91) |
| Evenpoel *et al.* | Belgium | 2015 | 5T | 268 | Male at risk | For coronary calcification, female β = -0.64, *p* < 0.0001  For thoracic aortic calcification, female β = -0.32, *p* = 0.008 | Coronary artery calcification (Agatston score) and thoracic aortic calcification | (117) |
| Fayed *et al.* | Egypt | 2019 | 5D (HD) | 81 | Neutral | Male β = 0.088, *p* = 0.695 | Abdominal aortic calcification by computed tomography | (118) |
| Filgueira *et al.* | Brazil | 2011 | 2-4 | 72 | Neutral | Female OR 0.149, *p* = 0.82 | Coronary artery calcification (Agatston score) | (119) |
| Floege *et al.* | Multicenter | 2010 | 5D (HD) | 360 | Male at risk for severe disease | Male β = 0.426, *p* = 0.0011 | Coronary artery calcification (Agatston score) | (92) |
| Fusaro *et al.* | Italy | 2015 | 5D (HD) | 314 | Neutral | Male OR 1.52 (0.87–2.66), *p* = 0.1 | Lateral lumbar radiography | (120) |
| Golembiewska *et al.* | Sweden | 2020 | 5, 5D | 149 | Male at risk | Male OR 4.4 (1.6–11.1), *p* = 0.003 | Inferior epigastric artery histopathology calcification grading | (121) |
| Gruppen *et al.* | Dutch | 2003 | 5D | 140 | Neutral | Male *p* > 0.05 | Aortic valve calcification on ultrasound | (122) |
| Harada *et al.* | Brazil | 2014 | 2-5 | 117 | Male at risk | Male OR 4.92 (2.07–11.70), *p* < 0.01 | Coronary artery calcification (Agatston score) | (33) |
| Ho et al. | Taiwan | 2019 | 5D | 61 | Male at risk | Male β= 1688.01, *p* = 0.02 | Coronary artery calcification (Agatston score) | (123) |
| Ishimura *et al.* | Japan | 2004 | 5D (HD) | 594 | Male at risk | For aortic calcification, male OR 2.339 (1.466–3.732), *p* = 0.0004  For hand artery calcification, male OR 1.857 (1.043–3.306), *p* = 0.0355 | Plain radiography of lateral abdomen and hand | (124) |
| Ishimura *et al.* | Japan | 2002 | 5D (HD) | 421 | Male at risk (subgroup) | In diabetics, male OR 3.38 (1.289-8.860), *p* = 0.0019  In non-diabetics, male OR 1.328 (0.252-6.997), *p* = 0.7376 | Digital artery calcification by hand radiography | (125) |
| Jankovic *et al.* | Serbia | 2017 | 5D (HD) | 90 | Male at risk and for severe disease | For VC presence, female OR 0.134 (0.04–0.45), *p* = 0.001  For VC severity, female β = –0.432 (-4.41– -1.86), *p* < 0.001 | Forearm AVF plain radiography | (38) |
| Jankovic *et al.* | Serbia | 2015 | 5D (HD) | 90 | Male at risk for severe disease | Composite calcification score, female β = -0.432, *p* < 0.001 | Plain radiography of pelvis and hands (Adragao score) + forearm AVF plain radiography | (39) |
| Jansson *et al.* | Sweden | 2019 | 3-4 | 84 | Neutral for overall risk but  male at risk for severe disease | Among total cohort, male not associated with AAC  Among those with AAC, male β = 0.413, *p* = 0.03 | Abdominal aortic calcification by computed tomography | (40) |
| Jean *et al* | France | 2009 | 5D (HD) | 161 | Neutral | Female OR 0.79 (0.3 – 1.8), *p* = 0.5 | Multi-site plain radiography involving pelvis, lumbar, knee, right hand, right arm, chest, skull, and orthopantomogram | (42) |
| Jean *et al.* | France | 2012 | 5D (HD) | 85 | Neutral | For calcification progression, female OR 0.51 (0.185–1.426), *p* = 0.2 | Multi-site plain radiography involving pelvis, lumbar, knee, right hand, right arm, chest, skull, and orthopantomogram | (43) |
| Jung *et al.* | South Korea | 2006 | 5D (HD) | 40 | Male at risk for progression | For calcification progression, male β = 1.365, *p* = 0.04 | Coronary artery calcification (Agatston score) | (126) |
| Kestenbaum *et al.* | United States | 2009 | 3-5 | 562 | Male at risk but not for progression | For VC presence, incidence rate ratio (IRR) 2.27 (1.26–4.09), *p* = 0.006  For VC progression, incidence rate ratio 1.10 (0.84-1.42), *p* = 0.5 | Coronary artery calcification (Agatston score) | (94) |
| Maia *et al.* | Brazil | 2018 | 5D (HD) | 309 | Female at risk | Female prevalence ratio 2.004 (1.012 –3.966) | Carotid artery calcification on panoramic radiographs | (95) |
| Manghat *et al.* | United Kingdom | 2011 | 1-4 | 145 | Neutral, but male at risk (in subgroup) | Overall, male β = 0.06, *p* =0.54  In those with CKD stage 4, male β = 0.29, t =2.04, *p* =0.049 | Pulse wave velocity based on a stiffness index | (127) |
| Maréchal *et al.* | Belgium | 2012 | 5T | 197 | Differential effect depending on calcification site | For coronary calcification, female progression, *p* > 0.05  For thoracic aortic calcification, female progression β = -0.09 (-0.17~-0.01), *p* = 0.03 | Coronary artery calcification (Agatston score) and thoracic artery calcification by computed tomography | (96) |
| Mazzaferro *et al.* | Italy | 2007 | 5D, 5T | 100 | Male at risk | Male OR 10.5 (3.2–34.4), *p* < 0.0001 | Coronary artery calcification (Agatston score) | (59) |
| Miyatake *et al.* | Japan | 2020 | 5T | 50 | Neutral | Female β = -0.051, p = 0.741 | Abdominal aortic calcification by computed tomography | (61) |
| Moldovan *et al.* | Romania | 2010 | 5D (HD) | 81 | Male at risk | Male OR 7.226 (1.138–45.882), *p* = 0.036 | Plain radiography of pelvis and hands (Adragao score) | (97) |
| Morena *et al.* | France | 2009 | 1-5 | 133 | Male at risk | Male OR 4.95 (2.36–10.37), *p* < 0.0001 | Coronary artery calcification (Agatston score) | (63) |
| Muntner *et al.* | United States | 2006 | 5D (HD) | 148 | Neutral | Prevalence rate ratio 1.37 (0.72–2.62) | Coronary artery calcification (Agatston score) | (98) |
| Nakayama *et al.* | Japan | 2013 | 5D (HD) | 47 | Male at risk | Female β = -0.407, *p* = 0.014 | Abdominal aortic calcification by computed tomography | (128) |
| Nishizawa *et al.* | Japan | 2015 | 5D (HD) | 207 | Neutral | Male β = -0.095, p = 0.174 | Coronary artery calcification (Agatston score) | (129) |
| Nishizawa *et al.* | Japan | 2004 | 5D (HD) | 332 | Male at risk | Male OR 3.380 (1.289-8.860), *p* = 0.0019 | Digital artery calcification by hand radiography | (130) |
| Nitta *et al.* | Japan | 2018 | 5D (HD) | 216 | Female at risk | Female β = 0.137 (0.021–0.254), *p* = 0.0206 | Aortic arch calcification on chest radiography | (65) |
| Okamoto *et al.* | Japan | 2018 | 5D (HD) | 184 | Male at risk for progression | Male OR 3.29 (1.27–8.53), *p* = 0.014 | Abdominal aorta calcification by computed tomography | (68) |
| Tamashiro *et al.* | Japan | 2002 | 5D (HD) | 24 | Male at risk progression | Male gender significant correlation with calcification progression | Pelvic and lumbar lateral radiography | (131) |
| Pateinakis *et al.* | Greece | 2013 | 5D (HD) | 81 | Neutral | β = -0.128, *p* = 0.15 | Pulse wave velocity | (132) |
| Porter *et al.* | United Kingdom | 2007 | 3-4 | 112 | Male at risk | Male OR 43.713 (2.92–654.0), *p* = 0.006 | Coronary artery calcification (Agatston score) | (99) |
| Qureshi *et al.* | Sweden | 2015 | 5T | 89 | Differential effect depending on calcification site | For epigastric artery, male RR 1.82 (1.03–1.16), *p* = 0.03  For coronary artery, male RR 0.83 (0.38-1.81), *p* = 0.63 | Biopsy-verified calcification in epigastric arteries and coronary artery calcification (Agatston score) | (70) |
| Raggi *et al.* | United States and Europe | 2002 | 5D (HD) | 205 | Differential effect depending on calcification site | For coronary artery calcification, female β = -0.587547, *p* = 0.0167  For aortic calcification, female β = -0.044508, *p* = 0.9036 | Coronary artery calcification (Agatston score) and aortic calcification by computed tomography | (133) |
| Schlieper *et al* | Serbia | 2008 | 5D (HD) | 212 | Male at risk | Male OR 3.95 (1.89–8.27), *p* = 0.0001 | Vascular access calcification by plain radiography | (75) |
| Schlieper *et al.* | Serbia | 2009 | 5D (HD) | 194 | Male at risk | For composite score, male OR 2.32 (1.19–4.52), *p* = 0.014  For Adragao score, male OR 2.75 (1.41–5.38), *p* = 0.003 | Plain radiography of pelvis and hands (Adragao score) + forearm AVF plain radiography + Cardiac ultrasound + Carotid ultrasound | (134) |
| Schlieper *et al.* | Serbia | 2008 | 5D (HD) | 212 | Male at risk | Male OR 5.08 (2.18–11.86), *p* = 0.0001 | Vascular access calcification on plain radiography | (75) |
| Sharma *et al.* | United Kingdom | 2007 | 5D | 140 | Neutral | Female OR 0.45 (0.16–0.81), *p* = 0.53 | Mitral annular calcification by cardiac ultrasound | (135) |
| Shu *et al.* | Taiwan | 2012 | 5T | 99 | Male at risk | Female β = -1.61, *p* = 0.0021 | Coronary artery calcification (Agatston score) | (76) |
| Sigrist *et al* | United Kingdom | 2007 | 4-5D | 134 | Male at risk for progression | For calcification progression at 2-yr, male OR 8.82 (1.82 to 42.65), *p* = 0.007 | Superficial femoral artery calcification by computed tomography | (77) |
| Sigrist et al. | United Kingdom | 2006 | 4-5D | 134 | Male at risk | Female β = -2.108, *p* < 0.001 | Superficial femoral artery calcification by computed tomography | (136) |
| Stavroulopoulos *et al.* | United Kingdom | 2011 | 3-4 | 112 | Male at risk for progression | Progression at 2-yr, male OR 27.808 (1.625–475.97), *p* = 0.022 | Coronary artery calcification (Agatston score) | (137) |
| Sumida *et al.* | Japan | 2010 | 5D | 135 | Neutral | Gender not associated with calcification | Carotid artery calcification by computed tomography | (138) |
| Tamei *et al.* | Japan | 2011 | 5D (HD) | 127 | Male at risk for progression | Progression at 5-yr, male β = 0.969, *p* = 0.0192 | Aortic arch calcification by chest radiography | (139) |
| Turan *et al.* | Turkey | 2016 | 5D (HD) | 224 | Male at risk | Male RR 4.14 (2.01–8.51), *p* < 0.001 | Coronary artery calcification (Agatston score) | (81) |
| Turan *et al.* | Turkey | 2013 | 5D (HD) | 191 | Male at risk | Male RR 2.79 (1.30–5.98), *p* = 0.008 | Coronary artery calcification (Agatston score) | (140) |
| Vipattawat *et al.* | Thailand | 2014 | 5, 5D,5T | 261 | Neutral | For 5T patients, OR 2.49 (0.87–7.14), *p* = 0.09  For 5 and 5D patients, OR 2.02 (0.71-5.78), *p* = 0.19 | Pelvic and lumbar spine lateral radiography | (141) |
| Wang *et al* | China | 2019 | 5D (HD) | 108 | Neutral | Female OR 0.56 (0.15–2.06), *p* = 0.38 | Abdominal aortic calcification (Kauppila score) | (100) |
| Wang *et al.* | China | 2014 | 5D (HD) | 77 | Male at risk | female OR 0.21 (0.07–0.58), *p* = 0.003 | Coronary artery calcification (Agatston score) | (101) |
| Yamada *et al.* | Japan | 2008 | 5D (HD) | 49 | Male at risk | Female β = -0.178, *p* = 0.0345 | Digital artery calcification by hand radiography | (142) |
| Tsai *et al.* | Taiwan | 2018 | 5D (PD) | 133 | Neutral | Higher AAC, male β = 1.139 (0.573–2.265), p = 0.710  Higher percentage (%) of AAC, male β = 0.424 (-5.650–6.498), p = 0.890 | AAC assessed with X-ray (Kauppila score) and computed tomography | (143) |
| Takayama *et al.* | Japan | 2015 | 3-5 | 126 | Neutral | Male OR 0.62 (0.24–1.56), p = 0.31 | Coronary artery calcification on computed tomography | (109) |
| Jasani *et* *al.* | India | 2018 | 5D (HD) | 126 | Neutral | Male OR 1.6 (0.3–8.8), p = 0.568 | Coronary artery calcification (Agatston score) | (144) |

*AAC, abdominal aortic calcification; AVF, arteriovenous fistula; CKD, chronic kidney disease; HD, hemodialysis; OR, odds ratio; RR, relative risk; VC, vascular calcification*

Table 3. Potential gender-related modifiers of vascular calcification in existing studies

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Authors | Country | Time | CKD stages | Sample size | Gender Effect | Data | Potential modifiers | Ref |
| Aoun *et al.* | Lebanon | 2017 | 5D (HD) | 50 | Male lower | <5000 vs. >5000 pmol/L, male 68.3% vs. 22.2%, *p* = 0.02 | Dp-ucMGP | (145) |
| Axelsson *et al.* | Sweden | 2008 | 5 | 198 | Male lower | Male β = –1.68, *p* < 0.001 | Total fat mass | (146) |
| Block et al. | United States | 1998 | 5D (HD) | 6407 | Female higher | Male OR 0.774, *p* = 0.0001 | Serum phosphorus > 6.5 mg/dL | (147) |
| Buiten MS | Netherlands | 2014 | 5D | 127 | Female higher | <460 vs. >460 pg/mL, female 16% vs 31%, *p* < 0.05 | Soluble Klotho | (148) |
| Cai *et al.* | China | 2015 | 5D (HD) | 129 | Neutral | ≤379 vs. 379-613 vs. 613-817 vs. >817 pg/mL, male 59.4% vs. 54.5% vs. 56.3% vs. 53.1%, *p* > 0.05 | Soluble Klotho | (116) |
| Chae *et al.* | Korea | 2018 | 1-5 | 1832 | Neutral | Quartile 1 (lowest) vs. 2 vs. 3 vs. 4, female 36.2% vs. 43.4% vs. 42.5% vs. 38.6%, *p* = 0.517 (mean, 6.76 pmol/L) | OPG | (90) |
| Chang et al. | Republic of Korea | 2012 | 5D (HD) | 289 | Female lower levels | Female OR 3.892 (1.678–9.025), *p* = 0.002 | Vitamin D (25-OH-D) deficiency (<15 ng/mL) | (11) |
| Chao *et al.* | Taiwan | 2019 | 5D | 223 | Neutral | High vs. low levels, female 63% vs. 51%, *p* = 0.14 | microRNA-125b | (149) |
| Chen *et al* | Sweden | 2017 | 5D, 5T | 240 | Neutral | Users vs. non-users, male 65% vs. 62%, *p* = 0.678 | Statin use | (15) |
| Chen *et al.* | Taiwan | 2013 | 5D (HD) | 238 | Neutral | Tertile 1 (lowest) vs. 2 vs. 3, female 55% vs. 48% vs. 57%, *p* = 0.5 | Fetuin-A | (150) |
| Choi *et al.* | Korea | 2019 | 5D (HD) | 97 | Neutral | Marker count 2 vs. 1 vs. 0, male 61.5% vs. 41.9% vs 34.1%, *p* = 0.216 | Nutritioon (albumin) and inflammation (CRP) markers | (18) |
| Claes *et al.* | Belgium | 2013 | 1-5 | 154 | Male higher | Male gender significantly associated with higher levels (*p* = 0.006) | Sclerostin | (151) |
| Evenpoel *et al.* | Belgium | 2015 | 5T | 268 | Male higher | Male gender significantly associated with higher levels (*p* = 0.002) | Sclerostin | (117) |
| Flávia Letícia et al. | Brazil | 2014 | 5D (HD) | 91 | Neutral | High vs low levels, male 68.9% vs. 52.2%, *p* = 0.103  Regression model, male OR 0.82 (0.39-1.75), *p* = 0.62 | Sclerostin | (152) |
| Golembiewska *et al.* | Sweden | 2020 | 5 | 149 | Neutral | High vs. middle vs. low levels, male 71% vs. 67% vs. 65%, *p* = 0.84  Regression model, male β -0.08, *p* = 0.31 | Copeptin | (121) |
| González-Parra E *et al.* | Spain | 2015 | 1-5 | 704 | Female higher in both | For PTH, male r = −0.084 (-0.155~-0.012), *p* = 0.0215  For FGF-23, male r = −0.191 (-0.301~-0.080), *p* = 0.0007 | Parathyroid hormone and FGF-23 | (153) |
| Gupta *et al* | Hungary | 2021 | 5D (HD) | 982 | Female higher | <3.2 vs. 3.2–4.39 vs. >4.39 pmol/L, male 63% vs. 57% vs. 52%, *p* = 0.015 | OPG | (154) |
| Harada *et al* | Brazil | 2014 | 2-5 | 117 | Male more severe | Area in males vs. females, 220.4 ± 110.5 vs. 135.4 ± 76.0, *p* < 0.001 | Pericardial fat | (33) |
| He *et al.* | China | 2018 | 5D (HD) | 150 | Neutral | Male correlation coefficient 0.106, *p* = 0.114 | Serum irisin | (34) |
| Holden *et al.* | Canada | 2014 | 3-5 | 167 | Neutral | CC vs. CG/GG, male 68% vs. 55%, *p* = 0.11 | VKORC1 (vitamin K epoxide reductase complex 1) polymorphism | (155) |
| Hou *et al.* | Taiwan | 2019 | 5D (HD) | 120 | Female lower | 72.97-237.13 vs. 237.36-323.54 vs. 329.61-835.78 pg/L, female 62.5% vs. 55.0% vs. 32.5%, *p* = 0.008 | OPG | (36) |
| Ikee *et al.* | Japan | 2016 | 5D (HD) | 86 | Neutral | Male vs. female, 2.51 ± 0.38 vs. 2.42 ± 0.33, *p* = 0.52 | Serum magnesium | (156) |
| Jean *et al.* | France | 2008 | 5D (HD) | 253 | Female lower levels | Deficient vs. sufficient, female 53% vs. 28%, *p* < 0.05 | Vitamin D (25-OH-D) deficiency | (157) |
| Jean *et al.* | France | 2011 | 5D (HD) | 1138 | Neutral | <50 vs. ≥50 pg/mL, female 43% vs. 40%, *p* > 0.05 | Parathyroid hormone | (158) |
| Jean *et al.* | France | 2016 | 5D (HD) | 227 | Female lower | Female OR 0.16 (0.075−0.362) | Sclerostin | (41) |
| Karsli Ceppioğlu *et al.* | Turkey | 2011 | 3-5 | 84 | Female higher | Female vs. male, higher in the former, *p* = 0.002 | Serum copper | (159) |
| Kato *et al.* | Japan | 2009 | 5D (HD) | 68 | Neutral | No correlation with gender | Serum pre-B cell colony-enhancing factor/visfatin | (160) |
| Kuo et al. | Taiwan | 2019 | 5D (PD) | 89 | Male higher | <80.2 vs. ≥80.2 pmol/L, male 36.4% vs. 62.2%, *p* = 0.015  Male OR 2.882 (1.219–6.815), p = 0.016 | Sclerostin | (161) |
| Liabeuf *et al.* | France | 2013 | 2-5, 5D | 139 | Neutral | ≤0.041 vs. >0.041 mg/dL, male 63% vs. 57%, *p* = 0.5 | Free p-cresylglucuronide | (162) |
| Metry *et al.* | Sweden | 2008 | 5D (HD) | 222 | Neutral | High Fetuin-A/Low CRP vs. High Fetuin-A/High CRP vs. Low Fetuin-A/Low CRP vs. Low Fetuin-A/High CRP, 60.9% vs. 52.5% vs. 44.4% vs. 58.8%, *p* > 0.05 | Fetuin-A and CRP | (163) |
| Miyatake *et al.* | Japan | 2020 | 5T | 50 | Female higher HDL, adiponectin but lower LDL | For LDL-C, male vs. female 113.0 (97.0–132.5) vs. 90.0 (76.5–98.3), *p* < 0.01  For HDL-C, male vs. female 57.0 (51.0–67.0) vs. 78.0 (66.8–96.5), *p* < 0.01  For HMW-ADPN, male vs. female 2.48 (1.62–3.33) vs. 4.52 (3.02–6.79), *p* < 0.01  For LMW-ADPN, male vs. female 1.67 (1.14–1.89) vs. 2.26 (1.85–2.83), *p* < 0.01  For CTRP9, male vs. female 2.08 (2.01–2.13) vs. 2.03 (2.00–2.07), *p* > 0.05 | Lipid profile, circulating C1q/TNF-a related protein-9 (CTRP9), and adiponectin | (61) |
| Nakashima *et al.* | Japan | 2010 | 5D (HD) | 151 | Neutral | Male β = 0.531, *p* = 0.51 | Osteoprotegerin | (164) |
| Nemeth *et al*. | Hungary | 2015 | 5T | 993 | Male lower | <3.2 vs. 3.2–4.39 vs. >4.39 pmol/L, male 63% vs. 58% vs. 52%, *p* = 0.02 | Osteoprotegerin | (165) |
| Nishiura *et al.* | Japan | 2009 | 5D (HD) | 99 | Male higher | Low vs. high, male 56% vs. 75.5%, *p* = 0.057  Male HR 3.034 (1.028–8.948), *p* = 0.044 | Osteoprotegerin | (166) |
| Okamoto *et al.* | Japan | 2018 | 5D (HD) | 230 | Neutral | <0.213 vs. ≥0.213 g/L, male 61% vs. 68%, *p* = 0.400  Male OR 0.48 (0.22-1.02), *p* = 0.056 | Fetuin-A | (167) |
| Park *et al.* | Korean | 2018 | 1-5 | 1741 | Neutral | Quartile 1 (lowest) vs. 2 vs. 3 vs. 4, male 80.6% vs. 59.0% vs. 39.7% vs. 39.6, *p* < 0.001  Male β = 0.095 (-0.421~0.231), *p* = 0.566 | ECF excess | (168) |
| Ramalho *et al* | Brazil | 2019 | 3-4 | 356 | Neutral | Tertile 1 (lowest) vs. 2 vs. 3, 59% vs. 64% vs.66%, *p* = 0.5  Male β = 0.22 (-0.02~0.45), *p* = 0.07 | Urinary calcium excretion | (169) |
| Scialla *et al.* | United States | 2011 | 1-5 | 351 | Female higher | 1.21-5.03 vs. 5.05-7.45 vs. 7.46-22.31 pmol/L, female 24.8% vs. 26.5% vs. 40.2%, *p* = 0.02  Female related OPG % difference 10.2%, *p* = 0.05 | Osteoprotegerin | (170) |
| Schlieper *et al.* | Serbia | 2011 | 5 | 188 | Neutral | <6139 vs. >6139 pmol/L, female OR 0.62 (0.35–1.11), *p* = 0.11 | dp-cMGP | (171) |
| Sigrist *et al.* | United Kingdom | 2009 | 3-4 | 134 | Neutral | ≤25 vs. >25 pmol/L, male 63% vs. 70%, *p* = 0.47 | Osteoprotegerin | (172) |
| Stenvinkel *et al.* | Sweden | 2005 | 5 | 258 | Neutral | Male vs. female, median 0.225 vs. 0.223 g/L, *p* > 0.05 | Fetuin-A | (173) |
| Stolic *et al.* | Serbia | 2016 | 5D (HD) | 88 | Neutral | Male vs. female, mean 1.2 (0.7–1.6) vs. 1.2 (0.8–1.5) mmol/L, *p* = 0.896 | Magnesium | (174) |
| Thambiah *et al.* | United Kingdom | 2012 | 3B-4 | 77 | Male higher | Male vs. female, mean 50.5 vs. 34 pmol/L, *p* = 0.015  Male β = 0.23, p = 0.024 | Sclerostin | (175) |
| Turan *et al.* | Turkey | 2016 | 5D (HD) | 224 | Neutral | <35.5 vs. 35.5-123.4 vs. >123.4 pg/mL, male 56.6% vs. 46.5% vs. 50.0%, *p* = 0.38 | FGF-23 | (81) |
| Turan *et al.* | Turkey | 2013 | 5D (HD) | 191 | Neutral | Low vs. middle vs. high, female 46% vs. 39% vs. 58%, *p* = 0.1 | Epicardial fat | (140) |
| Ulusoy *et al.* | Turkey | 2012 | 5D (HD) | 103 | Male higher | Pre-dialysis male vs. female levels, 314.7 ± 157.1 vs. 210.4 ± 115.4 ng/mL, *p* < 0.001 | Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) | (176) |
| Viaene *et al.* | Belgium | 2013 | 5D (HD) | 100 | Neutral | Low vs. high, female 47% vs. 35%, *p* = 0.2 | Sclerostin | (177) |
| Wang *et al.* | Hong Kong | 2014 | 3-5 | 300 | Male lower | Male correlation coefficient -0.14, *p* = 0.02 | Tissue AGEs (surrogated by skin autofluorescence) | (82) |
| Yoshikawa *et al.* | Japan | 2013 | 5D (HD) | 134 | Neutral | CC vs. CT vs. TT genotype, male 14% vs. 48% vs. 33%, *p* = 0.53 | MGP Genotype T-138C | (85) |
| Zhang *et al* | China | 2019 | 5D (HD) | 105 | Neutral | Quartile 1 (lowest) vs. 2 vs. 3 vs. 4, male 57.7% vs.48.1% vs. 46.2% vs. 65.4%, *p* = 0.473 | Soluble Klotho | (178) |
| Zhang *et al.* | China | 2015 | 5D (HD) | 90 | Male higher | ≤30 vs. 30-60 vs. ≥ 60 U/L, male 29.4% vs. 46.1% vs. 85.7%, *p* < 0.001  Male correlation coefficient 0.362, *p* < 0.001 | Serum ACE2 | (179) |
| Zou *et al.* | China | 2020 | 5D | 165 | Male higher | Among PD patients, male β = 0.259 (0.052–0.416), *p* = 0.012 | Sclerostin | (180) |
| Zou *et al.* | China | 2016 | 1-5 | 296 | Neutral | Tertile 1 (lowest) vs. 2 vs. 3, male 60.2% vs. 50.0% vs. 61.2%, *p* = 0.21 | Serum phosphorus | (181) |
| Sarmentos-Dias *et al.* | Portugal | 2017 | 5D (PD) | 61 | Neutral | Phase angle < 6° vs. > 6°, male 62% vs. 48% | Phase angle, which predicts vascular calcification | (182) |
| Kiss *et al.* | Hungary | 2013 | 5D | 5335 | Neutral | Male OR 1.09 (0.97–1.23), p > 0.05 | iPTH < 120 pg/ml | (183) |
| Marques *et al.* | Brazil | 2021 | 3-5 | 145 | Neutral | OPG ≤ vs. > 10.08 pmol/L, male 67.1% vs. 53.3%, p = 0.119 | Serum OPG | (184) |
| Khan et al. | United States | 2012 | 5D | 99 | Neutral | Low vs. mediate vs. high serum FGF-23, male 30% vs. 40% vs. 27%, p = 0.55 | Serum FGF-23 | (185) |
| Chen *et al.* | Taiwan | 2010 | 5D (HD) | 238 | Neutral | Fetuin A Tertile 0.15-0.25 vs. 0.26-0.32 vs. 0.33-0.51 g/L, female 55% vs. 48% vs. 57%, p = 0.8 | Fetuin-A | (186) |
| Schurgers *et al.* | France | 2010 | 2-5, 5D | 107 | Neutral | Plasma dp-ucMGP ≤ vs. > 921 pM, male 66% vs. 54%, p = 0.193 | Dp-ucMGP | (187) |
| Kestenbaum *et al.* | United States | 2005 | Serum creatinine ≥ 1.2 mg/dl (106.1 mol/L) for  women and ≥ 1.5 mg/dl (132.6 mol/L) for men | 6730 | Neutral | Serum phosphate < 2.5 vs. 2.5-3.499 vs. 3.5-4.499 vs. > 4.5, male 97.5% vs. 96.5% vs. 95.3% vs. 95.7% | Serum phosphate | (188) |
| Garland *et al.* | Canada | 2014 | 3-5 | 174 | Neutral | HOMA IR < vs. > 2.2, male 50% vs. 61%, p = 0.47 | Insulin resistance | (189) |

References

1. Ahmed S, O’Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J kidney Dis Off J Natl Kidney Found. 2001 Jun;37(6):1267–76.

2. Alayoud A, El Amrani M, Belarbi M, El Kharras A, Chtioui M, Elfilali K. Risk factors for progression of coronary artery calcification over 5 years in hemodialysis patients. Ann Cardiol Angeiol (Paris). 2020 Apr;69(2):81–5.

3. Al-Rifai R, Arabi A, Masrouji R, Daouk M. Prevalence of peripheral vascular calcifications in patients on chronic hemodialysis at a tertiary care center in Beirut: A pilot study. J Med Liban [Internet]. 2011;59(3):117–21. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=22259897&site=ehost-live&scope=site

4. Asci G, Ok E, Savas R, Ozkahya M, Duman S, Toz H, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant [Internet]. 2011;26(3):1010–5. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L361347859

5. Avramovski P, Avramovska M, Sotiroski K, Sikole A. Acute-phase proteins as promoters of abdominal aortic calcification in chronic dialysis patients. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2019;30(2):376–86.

6. Bae E, Seong EY, Han B-G, Kim DK, Lim CS, Kang S-W, et al. Coronary artery calcification in Korean patients with incident dialysis. Hemodial Int. 2017;21(3):367–74.

7. Ballotta E, Renon L, Toffano M, Piccoli A, Da Giau G. Patency and limb salvage rates after distal revascularization to unclampable calcified outflow arteries. J Vasc Surg [Internet]. 2004;39(3):539–46. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=14981445&site=ehost-live&scope=site

8. Bellasi A, Block GA, Ferramosca E, Ratti C, Raggi P. Integration of clinical and imaging data to predict death in hemodialysis patients. Hemodial Int. 2013 Jan;17(1):12–8.

9. Bundy JD, Cai X, Mehta RC, Scialla JJ, de Boer IH, Hsu C-Y, et al. Serum Calcification Propensity and Clinical Events in CKD. Clin J Am Soc Nephrol. 2019 Nov;14(11):1562–71.

10. Chandra A, Raj G, Awasthi NP, Rao N, Srivastava D. Evaluation of the relationship between blood cell parameters and vascular calcification in dialysis-dependent end-stage renal disease patients. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2020;31(1):136–43.

11. Chang JH, Ro H, Kim S, Lee HH, Chung W, Jung JY. Study on the relationship between serum 25-hydroxyvitamin D levels and vascular calcification in hemodialysis patients with consideration of seasonal variation in vitamin D levels. Atherosclerosis. 2012;220(2):563–8.

12. Chao C-T. A combined microrna and target protein-based panel for predicting the probability and severity of uremic vascular calcification. J Am Soc Nephrol [Internet]. 2020;31:177–8. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L633703091&from=export

13. Chao C-T, Liu Y-P, Su S-F, Yeh H-Y, Chen H-Y, Lee P-J, et al. Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification. Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1402–14.

14. Charitaki E, Davenport A. Aortic pulse wave velocity in haemodialysis patients is associated with the prescription of active vitamin D analogues. J Nephrol. 2014 Aug;27(4):431–7.

15. Chen Z, Qureshi AR, Parini P, Hurt-Camejo E, Ripsweden J, Brismar TB, et al. Does statins promote vascular calcification in chronic kidney disease? Eur J Clin Invest [Internet]. 2017;47(2):137–48. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L614236354

16. Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol. 2017;2(6):635–43.

17. Chiu Y-W, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R, et al. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int [Internet]. 2010;77(12):1107–14. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=105217265&site=ehost-live&scope=site

18. Choi SR, Lee Y-K, Cho AJ, Park HC, Han CH, Choi M-J, et al. Malnutrition, inflammation, progression of vascular calcification and survival: Inter-relationships in hemodialysis patients. PLoS One. 2019;14(5):e0216415.

19. Chue CD, Wall NA, Crabtree NJ, Zehnder D, Moody WE, Edwards NC, et al. Aortic calcification and femoral bone density are independently associated with left ventricular mass in patients with chronic kidney disease. PLoS One [Internet]. 2012;7(6). Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L365024006

20. Claes KJ, Heye S, Bammens B, Kuypers DR, Meijers B, Naesens M, et al. Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. Transpl Int [Internet]. 2013;26(10):973–81. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52694576

21. Coen G, Manni M, Agnoli A, Balducci A, Dessi M, De Angelis S, et al. Cardiac calcifications: Fetuin-A and other risk factors in hemodialysis patients. ASAIO J. 2006;52(2):150–6.

22. Coll B, Betriu A, Martinez-Alonso M, Amoedo ML, Arcidiacono MV, Borras M, et al. Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis. Clin J Am Soc Nephrol. 2011;6(2):303–10.

23. Craver L, Dusso A, Martinez-Alonso M, Sarro F, Valdivielso JMJMJM, Fernandez E, et al. A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients. BMC Nephrol [Internet]. 2013;14(1). Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52814371

24. Davis B, Marin D, Hurwitz LM, Ronald J, Ellis MJ, Ravindra K V, et al. Application of a Novel CT-Based Iliac Artery Calcification Scoring System for Predicting Renal Transplant Outcomes. Am J Roentgenol. 2016;206(2):436–41.

25. DeLoach SS, Joffe MM, Mai X, Goral S, Rosas SE. Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant. 2009;24(4):1314–9.

26. Di Iorio BR, Bortone S, Piscopo C, Grimaldi P, Cucciniello E, D’Avanzo E, et al. Cardiac vascular calcification and QT interval in ESRD patients: Is there a link? Blood Purif [Internet]. 2006;24(5–6):451–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L46030087

27. Disthabanchong S, Vipattawat K, Phakdeekitcharoen B, Kitiyakara C, Sumethkul V. Abdominal aorta and pelvic artery calcifications on plain radiographs may predict mortality in chronic kidney disease, hemodialysis and renal transplantation. Int Urol Nephrol [Internet]. 2018;50(2):355–64. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L619734828

28. El Amrani M, Maoujoud O, Belarbi M, El Farouki MR, Zajjari Y, Boukili Y, et al. Screening and risk factors of cardiac calcification in hemodialysis: contribution of ultra-fast multi-slice scanner and transthoracic echocardiography. Ann Cardiol Angeiol (Paris). 2015;64(2):87–93.

29. Etta PK, Sharma RK, Gupta A. Study of chronic kidney disease-mineral bone disorders in newly detected advanced renal failure patients: A Hospital-based cross-sectional study. Saudi J Kidney Dis Transplant An Off Publ Saudi Cent Organ Transplantation, Saudi Arab [Internet]. 2017;28(4):874–85. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=28748891&site=ehost-live&scope=site

30. Fabbian F, Catalano C, Orlandi V, Conte MM, Lupo A, Catizone L. Evaluation of aortic arch calcification in hemodialysis patients. J Nephrol [Internet]. 2005;18(3):289–93. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16013017&site=ehost-live&scope=site

31. Fayed A, Soliman A, El Mahdy H, Hamza W, Abdulazim DO, Salem MM, et al. Intraoperative Arterial Biopsy in Incident Hemodialysis Patients: Differences Observed. Nephron. 2019;143(1):54–61.

32. Gunen Yilmaz S, Yilmaz F, Bayrakdar IS, Harorli A. The Relationship between carotid artery calcification and pulp stone among hemodialysis patients: A retrospective study. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2019;30(4):755–63.

33. Harada PHN, Canziani ME, Lima LM, Kamimura M, Rochitte CE, Lemos MM, et al. Pericardial fat is associated with coronary artery calcification in non-dialysis dependent chronic kidney disease patients. PLoS One [Internet]. 2014;9(12):e114358–e114358. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=25479288&site=ehost-live&scope=site

34. He L, He W-Y, A L-T, Yang W-L, Zhang A-H. Lower Serum Irisin Levels Are Associated with Increased Vascular Calcification in Hemodialysis Patients. Kidney Blood Press Res [Internet]. 2018;43(1):287–95. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=29490308&site=ehost-live&scope=site

35. He J, Reilly M, Yang W, Chen J, Go AS, Lash JP, et al. Risk factors for coronary artery calcium among patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study). Am J Cardiol. 2012;110(12):1735–41.

36. Hou J-S, Lin Y-L, Wang C-H, Lai Y-H, Kuo C-H, Subeq Y-M, et al. Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid-femoral pulse wave velocity in hemodialysis patients: a cross sectional study. BMC Nephrol [Internet]. 2019;20(1):N.PAG-N.PAG. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=136621379&site=ehost-live&scope=site

37. H. AH, N. A-H, A.A.M.H. A, V.T. N, M.R.N. N, A.M. R, et al. Vascular calcification in dialysis patients. Transplant Proc [Internet]. 2005;37(10):4183–6. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L43015985

38. Jankovic A, Damjanovic T, Djuric Z, Marinkovic J, Schlieper G, Djuric P, et al. Calcification in arteriovenous fistula blood vessels may predict arteriovenous fistula failure: a 5-year follow-up study. Int Urol Nephrol [Internet]. 2017;49(5):881–7. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L614230135

39. Jankovic A, Damjanovic T, Djuric Z, Marinkovic J, Schlieper G, Tosic-Dragovic J, et al. Impact of Vascular Calcifications on Arteriovenous Fistula Survival in Hemodialysis Patients: A Five-Year Follow-Up. Nephron. 2015;129(4):247–52.

40. Jansson H, Saeed A, Svensson MK, Finnved K, Hellström M, Guron G. Impact of Abdominal Aortic Calcification on Central Haemodynamics and Decline of Glomerular Filtration Rate in Patients with Chronic Kidney Disease Stages 3 and 4. Kidney Blood Press Res [Internet]. 2019;44(5):950–60. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L629160945

41. Jean G, Chazot C, Bresson E, Zaoui E, Cavalier E. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Nephron. 2016;132(3):181–90.

42. Jean G, Bresson E, Terrat J-C, Vanel T, Hurot J-M, Lorriaux C, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant [Internet]. 2009;24(3):948–55. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L354216091

43. Jean G, Bresson E, Lorriaux C, Mayor B, Hurot J-M, Deleaval P, et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin Pract. 2012;120(3):c132-8.

44. Jiménez Villodres M, García Gutiérrez G, García Frías P, Rioja Villodres J, Martín Velázquez M, Sánchez Chaparro MÁ, et al. Fractional excretion of phosphorus and vascular calcification in stage 3 chronic kidney disease. J Investig Med Off Publ Am Fed Clin Res. 2019 Mar;67(3):674–80.

45. Kahn J, Ram LM, Eberhard K, Groselj-Strele A, Obermayer-Pietsch B, Mueller H. Calcification score evaluation in patients listed for renal transplantation. Clin Transplant. 2017;31(3).

46. Keyzer CA, de Borst MH, van den Berg E, Jahnen-Dechent W, Arampatzis S, Farese S, et al. Calcification Propensity and Survival among Renal Transplant Recipients. J Am Soc Nephrol. 2016 Jan;27(1):239–48.

47. Kim SM, Jung IM, Kim D, Lee JP, So YH. Effect of Inflow Arterial Calcification on Arteriovenous Fistula Maturation. Ann Vasc Surg. 2019 Jul;58:331–7.

48. Kim HG, Song SW, Kim TY, Kim YO. Risk factors for progression of aortic arch calcification in patients on maintenance hemodialysis and peritoneal dialysis. Hemodial Int [Internet]. 2011;15(4):460–7. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L362808583

49. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl. 1999;71:S238-41.

50. Komatsu M, Okazaki M, Tsuchiya K, Kawaguchi H, Nitta K. Aortic Arch Calcification Predicts Cardiovascular and All-Cause Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res. 2014;39(6):658–67.

51. Lee C Te, Huang CC, Hsu CY, Chiou TTY, Ng HY, Wu CH, et al. Calcification of the aortic arch predicts cardiovascular and all-cause mortality in chronic hemodialysis patients. CardioRenal Med [Internet]. 2014;4(1):34–42. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L603943439

52. Lee C-T, Lee Y-T, Tain Y-L, Ng H-Y, Kuo W-H. Circulating microRNAs and vascular calcification in hemodialysis patients. J Int Med Res. 2019 Jul;47(7):2929–39.

53. Lee MJ, Park JT, Park KS, Kwon YE, Han SH, Kang S-W, et al. Normal body mass index with central obesity has increased risk of coronary artery calcification in Korean patients with chronic kidney disease. Kidney Int. 2016;90(6):1368–76.

54. Lioufas NM, Pedagogos E, Hawley CM, Pascoe EM, Elder GJ, Badve S V, et al. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial. Am J Nephrol. 2020;51(3):201–15.

55. Liu J, Zhang L, Zhou Y, Zhu D, Wang Q, Hao L. Aberrant activation of Wnt pathways in arteries associates with vascular calcification in chronic kidney disease. Int Urol Nephrol. 2016;48(8):1313–9.

56. Lockhart ME, Robbin ML, McNamara MM, Allon M. Association of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients. Nephrol Dial Transplant [Internet]. 2004;19(10):2564–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L39360105

57. London GM, Pannier B, Marchais SJ. Vascular calcifications, arterial aging and arterial remodeling in ESRD. Blood Purif. 2013;35(1–3):16–21.

58. Maharem DA, Gomaa SH, El Ghandor MK, Mohamed EI, Matrawy KA, Zaytoun SS, et al. Association of serum fetuin-A and fetuin-A gene polymorphism in relation to mineral and bone disorders in patients with chronic kidney disease. Egypt J Med Hum Genet [Internet]. 2013;14(4):337–52. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L369999530

59. Mazzaferro S, Pasquali M, Pugliese F, Barresi G, Carbone I, Francone M, et al. Serum levels of calcification inhibition proteins and coronary artery calcium score: Comparison between transplantation and dialysis. Am J Nephrol [Internet]. 2007;27(1):75–83. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L46364544

60. Merjanian R, Budoff M, Adler S, Berman N, Mehrotra R. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int [Internet]. 2003;64(1):263–71. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L36714180

61. Miyatake N, Adachi H, Nomura-Nakayama K, Okada K, Okino K, Hayashi N, et al. Circulating CTRP9 correlates with the prevention of aortic calcification in renal allograft recipients. PLoS One. 2020;15(1):e0226526.

62. Mizuiri S, Nishizawa Y, Yamashita K, Mizuno K, Ishine M, Doi S, et al. Coronary artery calcification score and common iliac artery calcification score in non-dialysis CKD patients. Nephrology (Carlton). 2018 Sep;23(9):837–45.

63. M. M, A.-M. D, I. J, H. V, G. G, K. K, et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant [Internet]. 2009;24(11):3389–97. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L358385284

64. Munguia P, Caramelo R, Rubio M V, Sahdala L, Arnaudas L, Paul J, et al. Pre-Transplant Assessment of Vascular Calcification as a Risk Factor of Mortality, Graft Loss, and Cardiovascular Events in Renal Transplant Recipients. Transplant Proc. 2015;47(8):2368–70.

65. Nitta K, Hanafusa N, Okazaki M, Komatsu M, Kawaguchi H, Tsuchiya K. Association Between Risk Factors Including Bone-Derived Biomarkers and Aortic Arch Calcification in Maintenance Hemodialysis Patients. Kidney Blood Press Res [Internet]. 2018;43(5):1554–62. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L624716127

66. Niu Q, Zhao H, Wu B, Tsai S, Wu J, Zhang M, et al. Abdominal aortic calcification is superior to other arteries calcification in predicting the mortality in peritoneal dialysis patients - a 8 years cohort study. BMC Nephrol. 2019 Dec;20(1):439.

67. Niu Q, Yang S, Gan L, Zhao H, Zuo L. Different type and dosage of heparin were not associated with the progression of coronary artery calcification in haemodialysis patients. Nephrology (Carlton). 2020 Jul;25(7):551–8.

68. Okamoto T, Hatakeyama S, Kodama H, Horiguchi H, Kubota Y, Kido K, et al. The relationship between poor nutritional status and progression of aortic calcification in patients on maintenance hemodialysis. BMC Nephrol. 2018;19.

69. Petrovic M, Baralic M, Brkovic V, Arsenovic A, Stojanov V, Lalic N, et al. Significance of acPWV for Survival of Hemodialysis Patients. Medicina (Kaunas). 2020 Aug;56(9).

70. Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. KIDNEY Int. 2015;88(6):1356–64.

71. Raggi P, Bellasi A, Gamboa C, Ferramosca E, Ratti C, Block GA, et al. All-cause mortality in hemodialysis patients with heart valve calcification. Clin J Am Soc Nephrol. 2011 Aug;6(8):1990–5.

72. Renaud H, Atik A, Herve M, Moriniere P, Hocine C, Belbrik S, et al. Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate. Nephron. 1988;48(1):28–32.

73. Ribeiro S, Ramos A, Brandão A, Rebelo JR, Guerra A, Resina C, et al. Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant [Internet]. 1998;13(8):2037–40. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L28356772

74. Roca-Tey R, Paez R, Rivas A, Samon R, Ibrik O, Gimenez I, et al. Prevalence and functional effect of arteriovenous fistula calcifications, evaluated by spiral CT in chronic haemodialysis patients. NEFROLOGIA. 2009;29(3):214–21.

75. Schlieper G, Krüger T, Djuric Z, Damjanovic T, Markovic N, Schurgers LJ, et al. Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int [Internet]. 2008;74(12):1582–7. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=105591391&site=ehost-live&scope=site

76. Shu K-H, Tsai I-C, Ho H-C, Wu M-J, Chen C-H, Cheng C-H, et al. Coronary artery calcification in kidney transplant recipients with long-term follow-up. Transplant Proc [Internet]. 2012;44(3):687–90. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=22483469&site=ehost-live&scope=site

77. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(6):1241–8.

78. Strózecki P, Odrowaz-Sypniewska G, Manitius J. Cardiac valve calcifications and left ventricular hypertrophy in hemodialysis patients. Ren Fail. 2005;27(6):733–8.

79. K. T, A. D, Tangvoraphonkchai K, Davenport A. Reduction in Aortic Pulse Wave Velocity Is Associated with a Short-Term Reduction in Dual-Energy X-Ray Absorptiometry Lumbar Spine Bone Mineral Density T Score. Blood Purif [Internet]. 2019;1–5. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L628687376

80. Tomiyama C, Carvalho AB, Higa A, Jorgetti V, Draibe SA, Canziani MEF. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res. 2010;25(3):499–504.

81. Turan MN, Kircelli F, Yaprak M, Sisman AR, Gungor O, Bayraktaroglu S, et al. FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients. Int Urol Nephrol. 2016;48(4):609–17.

82. Wang AY-M, Wong C-K, Yau Y-Y, Wong S, Chan IH-S, Lam CW-K. Skin autofluorescence associates with vascular calcification in chronic kidney disease. Arterioscler Thromb Vasc Biol. 2014;34(8):1784–90.

83. Wang AYM, Wang M, Woo J, Lam CWK, Li PKT, Lui S fai, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol. 2003;14(1):159–68.

84. Wu C-F, Lee Y-F, Lee W-J, Su C-T, Lee LJ-H, Wu K-D, et al. Severe aortic arch calcification predicts mortality in patients undergoing peritoneal dialysis. J Formos Med Assoc. 2017;116(5):366–72.

85. Yoshikawa K, Abe H, Tominaga T, Nakamura M, Kishi S, Matsuura M, et al. Polymorphism in the human matrix Gla protein gene is associated with the progression of vascular calcification in maintenance hemodialysis patients. Clin Exp Nephrol. 2013;17(6):882–9.

86. Zhou Y, Hellberg M, Kouidi E, Deligiannis A, Hoglund P, Clyne N. Relationships between abdominal aortic calcification, glomerular filtration rate, and cardiovascular risk factors in patients with non-dialysis dependent chronic kidney disease. Clin Nephrol. 2018;90(6):380–9.

87. Abd Alamir M, Radulescu V, Goyfman M, Mohler 3rd ER, Gao YL, Budoff MJ. Prevalence and correlates of mitral annular calcification in adults with chronic kidney disease: Results from CRIC study. Atherosclerosis [Internet]. 2015;242(1):117–22. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=26188533&site=ehost-live&scope=site

88. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Gonçalves M, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant [Internet]. 2004;19(6):1480–8. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L38786742

89. Bundy JD, Cai X, Scialla JJ, Dobre MA, Chen J, Hsu C-Y, et al. Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J kidney Dis Off J Natl Kidney Found. 2019 Jun;73(6):806–14.

90. Chae SY, Chung W, Kim YH, Oh YK, Lee J, Choi KH, et al. The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study. J Korean Med Sci. 2018;33(53):e322–e322.

91. Dai L, Debowska M, Lukaszuk T, Bobrowski L, Barany P, Söderberg M, et al. Phenotypic features of vascular calcification in chronic kidney disease. J Intern Med. 2020 Apr;287(4):422–34.

92. Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25(6):1916–23.

93. Gelev S, Spasovski G, Trajkovski Z, Damjanovski G, Amitov V, Selim G, et al. Factors associated with various arterial calcifications in haemodialysis patients. Prilozi [Internet]. 2008;29(2):185–99. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=19259046&site=ehost-live&scope=site

94. Kestenbaum BR, Adeney KL, de Boer IH, Ix JH, Shlipak MG, Siscovick DS, et al. Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. Kidney Int [Internet]. 2009;76(9):991–8. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L50616874

95. Maia PRL, Medeiros AMC, Pereira HSG, Lima KC, Oliveira PT. Presence and associated factors of carotid artery calcification detected by digital panoramic radiography in patients with chronic kidney disease undergoing hemodialysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126(2):198–204.

96. Maréchal C, Coche E, Goffin E, Dragean A, Schlieper G, Nguyen P, et al. Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J kidney Dis Off J Natl Kidney Found. 2012 Feb;59(2):258–69.

97. Leckstroem DCT, Bhuvanakrishna T, McGrath A, Goldsmith DJA. Prevalence and predictors of abdominal aortic calcification in healthy living kidney donors. Int Urol Nephrol. 2014;46(1):63–70.

98. Muntner P, Ferramosca E, Bellasi A, Block GA, Raggi P. Development of a cardiovascular calcification index using simple imaging tools in haemodialysis patients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2007 Feb;22(2):508–14.

99. Porter CJ, Stavroulopoulos A, Roe SD, Pointon K, Cassidy MJD. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2007;22(11):3208–13.

100. Wang Y, Miao Y, Gong K, Cheng X, Chen Y, Zhao M-H. Plasma Complement Protein C3a Level Was Associated with Abdominal Aortic Calcification in Patients on Hemodialysis. J Cardiovasc Transl Res. 2019;

101. Wang M, Li H, You L, Yu X, Zhang M, Zhu R, et al. Association of Serum Phosphorus Variability with Coronary Artery Calcification among Hemodialysis Patients. PLoS One. 2014;9(4).

102. Stefan G, Capusa C, Stancu S, Petrescu L, Nedelcu ED, Andreiana I, et al. Abdominal aortic calcification and renal resistive index in patients with chronic kidney disease: is there a connection? J Nephrol. 2014 Apr;27(2):173–9.

103. Tomiyama C, Higa A, Dalboni MA, Cendoroglo M, Draibe SA, Cuppari L, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2006 Sep;21(9):2464–71.

104. Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Fernandes Canziani ME. Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population. Nephron Clin Pract. 2006;104(1):c33-40.

105. Chavent B, Maillard N, Boutet C, Albertini J-N, Duprey A, Favre J-P. Prognostic Value of Aortoiliac Calcification Score in Kidney Transplantation Recipients. Ann Vasc Surg. 2017 Oct;44:245–52.

106. Tian Y, Feng S, Zhan Z, Lu Y, Wang Y, Jiang S, et al. Risk Factors for New-Onset Cardiac Valve Calcification in Patients on Maintenance Peritoneal Dialysis. Cardiorenal Med. 2016 Feb;6(2):150–8.

107. Ulutas O, Taskapan MC, Dogan A, Baysal T, Taskapan H. Vascular calcification is not related to serum fetuin-A and osteopontin levels in hemodialysis patients. Int Urol Nephrol. 2018;50(1):137–42.

108. Turkmen K, Gorgulu N, Uysal M, Ozkok A, Sakaci T, Unsal A, et al. Fetuin-A, inflammation, and coronary artery calcification in hemodialysis patients. Indian J Nephrol. 2011 Apr;21(2):90–4.

109. Takayama Y, Yasuda Y, Suzuki S, Shibata Y, Tatami Y, Shibata K, et al. Relationship between abdominal aortic and coronary artery calcification as detected by computed tomography in chronic kidney disease patients. Heart Vessels. 2016 Jul;31(7):1030–7.

110. Tsukada M, Miwa N, Hanafusa N, Tanaka N, Tsuchiya K, Nitta K. Aortic Arch Calcification and Bone-Associated Molecules in Peritoneal Dialysis Patients. Blood Purif. 2019;47 Suppl 2:81–7.

111. El Baz TZ, Khamis OA, Ahmed Gheith OA, Abd Ellateif SS, Abdallah AM, Abd El Aal HC. Relation of fibroblast growth factor-23 and cardiovascular calcification in end-stage kidney disease patients on regular hemodialysis. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2017;28(1):51–60.

112. Moldovan D, Moldovan I, Rusu C, Kacso I, Patiu IM, Gherman-Caprioara M. FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients. Int Urol Nephrol. 2014 Jan;46(1):121–8.

113. Lee Y-T, Ng H-Y, Chiu TT-Y, Li L-C, Pei S-N, Kuo W-H, et al. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. Clin Chim Acta. 2016 Jan;452:38–43.

114. Bellasi A, Veledar E, Ferramosca E, Ratti C, Block G, Raggi P, et al. Markers of vascular disease do not differ in black and white hemodialysis patients despite a different risk profile. Atherosclerosis [Internet]. 2008;197(1):242–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L351273245

115. Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2011;58(4):519–26.

116. Cai H, Lu R, Zhang M, Pang H, Zhu M, Zhang W, et al. Serum Soluble Klotho Level Is Associated with Abdominal Aortic Calcification in Patients on Maintenance Hemodialysis. Blood Purif. 2015;40(2):120–6.

117. Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, et al. Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab [Internet]. 2015;100(12):4669–76. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=113977572&site=ehost-live&scope=site

118. Fayed A, Elnokeety MM, Attia K, Sharaf El Din UA. Calcification of abdominal aorta in patients recently starting hemodialysis: A single-center experience from Egypt. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2019;30(4):819–24.

119. Filgueira A, Carvalho AB, Tomiyama C, Higa A, Rochitte CE, Santos RD, et al. Is Coronary Artery Calcification Associated with Vertebral Bone Density in Nondialyzed Chronic Kidney Disease Patients? Clin J Am Soc Nephrol. 2011;6(6):1456–62.

120. Fusaro M, Gallieni M, Rebora P, Rizzo MA, Luise MC, Riva H, et al. Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in hemodialysis patients. J Nephrol [Internet]. 2016;29(3):419–26. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L610468679

121. Golembiewska E, Qureshi AR, Dai L, Lindholm B, Heimbürger O, Söderberg M, et al. Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5. BMC Nephrol [Internet]. 2020 Feb 7;21(1):43. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=32033584&site=ehost-live&scope=site

122. Gruppen MP, Groothoff JW, Prins M, van der Wouw P, Offringa M, Bos WJ, et al. Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int. 2003 Mar;63(3):1058–65.

123. Ho T-Y, Chen N-C, Hsu C-Y, Huang C-W, Lee P-T, Chou K-J, et al. Evaluation of the association of Wnt signaling with coronary artery calcification in patients on dialysis with severe secondary hyperparathyroidism. BMC Nephrol. 2019;20(1):345.

124. Bover J, Ureña-Torres P, Cozzolino M, Rodríguez-García M, Gómez-Alonso C. The Non-invasive Diagnosis of Bone Disorders in CKD. Calcif Tissue Int [Internet]. 2021 Jan 4; Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=33398414&site=ehost-live&scope=site

125. Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, et al. Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patientsn - Importance of glycaemic control. Diabetologia [Internet]. 2002;45(10):1446–8. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L35244899

126. Jung HH, Kim S-W, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21(7):1915–20.

127. Manghat P, Souleimanova I, Cheung J, Wierzbicki AS, Harrington DJ, Shearer MJ, et al. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone [Internet]. 2011 May 1;48(5):1127–32. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=21281749&site=ehost-live&scope=site

128. Nakayama K, Nakao K, Takatori Y, Inoue J, Kojo S, Akagi S, et al. Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. Int J Nephrol Renovasc Dis. 2013;7:25–33.

129. Nishizawa Y, Mizuiri S, Yorioka N, Hamada C, Tomino Y. Determinants of coronary artery calcification in maintenance hemodialysis patients. J Artif Organs Off J Japanese Soc Artif Organs [Internet]. 2015;18(3):251–6. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=25805429&site=ehost-live&scope=site

130. Nishizawa Y, Jono S, Ishimura E, Shioi A. Hyperphosphatemia and vascular calcification in end-stage renal disease. J Ren Nutr [Internet]. 2005;15(1):178–82. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L40093705

131. Oprisiu R, Bunea D, Tarek S, Hedi B, Fournier A. Progression of vascular calcification and dyslipidemia in patients on chronic hemodialysis [Internet]. Vol. 39, American Journal of Kidney Diseases. 2002. p. 209. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0272638614700988

132. Pateinakis P, Papagianni A, Douma S, Efstratiadis G, Memmos D. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol. 2013;14.

133. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, et al. Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol [Internet]. 2002;39(4):695–701. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L34158168

134. Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic N, Schurgers L, et al. Risk factors for cardiovascular calcifications in non-diabetic Caucasian haemodialysis patients. Kidney Blood Press Res [Internet]. 2009;32(3):161–8. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L50530012

135. Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP, et al. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease. Atherosclerosis. 2007 Apr;191(2):348–54.

136. Sigrist M, Bungay P, Taal MW, McIntyre CW. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant [Internet]. 2006;21(3):707–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16263735

137. Stavroulopoulos A, Porter CJ, Pointon K, Monaghan JM, Roe SD, Cassidy MJD. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant [Internet]. 2011;26(8):2582–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L362261849

138. Sumida Y, Nakayama M, Nagata M, Nakashita S, Suehiro T, Kaizu Y, et al. Carotid artery calcification and atherosclerosis at the initiation of hemodialysis in patients with end-stage renal disease. Clin Nephrol [Internet]. 2010;73(5):360–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L358729373

139. Tamei N, Ogawa T, Ishida H, Ando Y, Nitta K. Serum Fibroblast Growth Factor-23 Levels and Progression of Aortic Arch Calcification in Non-Diabetic Patients on Chronic Hemodialysis. J Atheroscler Thromb. 2011;18(3):217–23.

140. Turan MN, Gungor O, Asci G, Kircelli F, Acar T, Yaprak M, et al. Epicardial adipose tissue volume and cardiovascular disease in hemodialysis patients. Atherosclerosis [Internet]. 2013;226(1):129–33. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52305037

141. Vipattawat K, Kitiyakara C, Phakdeekitcharoen B, Kantachuvesiri S, Sumethkul V, Jirasiritham S, et al. Vascular calcification in long-term kidney transplantation. Nephrology [Internet]. 2014;19(4):251–6. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L372702733

142. Yamada S, Inaba M, Shidara K, Okada S, Emoto M, Ishimura E, et al. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci. 2008 Sep;83(13–14):516–9.

143. Tsai C-H, Lin C, Ho Y-H, Lo M-T, Liu L-YD, Lin C-T, et al. The association between heart rhythm complexity and the severity of abdominal aorta calcification in peritoneal dialysis patients. Sci Rep. 2018 Oct;8(1):15627.

144. Jasani R, Hase N, Kumar R, Dedhia P, Jamale T, Bajpai D. Predictors of coronary calcification in Indian hemodialysis patients. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2018;29(4):822–7.

145. Aoun M, Makki M, Azar H, Matta H, Chelala DN. High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K(2), A pre-post intervention clinical trial. BMC Nephrol. 2017 Jun;18(1):191.

146. Axelsson J, Wang X, Ketteler M, Qureshi AR, Heimbürger O, Bárány P, et al. Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease? Am J Nephrol. 2008;28(4):669–76.

147. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J kidney Dis Off J Natl Kidney Found. 1998 Apr;31(4):607–17.

148. Buiten MS, de Bie MK, Bouma-de Krijger A, van Dam B, Dekker FW, Jukema JW, et al. Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients. BMC Nephrol. 2014 Dec;15:197.

149. Chao C-T, Yuan T-H, Yeh H-Y, Chen H-Y, Huang J-W, Chen H-W. Risk Factors Associated With Altered Circulating Micro RNA -125b and Their Influences on Uremic Vascular Calcification Among Patients With End-Stage Renal Disease. J Am Heart Assoc. 2019 Jan;8(2):e010805.

150. Chen H-Y, Chiu Y-L, Hsu S-P, Pai M-F, Yang J-Y, Peng Y-S. Low serum fetuin A levels and incident stroke in patients with maintenance haemodialysis. Eur J Clin Invest. 2013 Apr;43(4):387–96.

151. Claes KJ, Viaene L, Heye S, Meijers B, D’Haese P, Evenepoel P. Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab [Internet]. 2013;98(8):3221–8. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L369563218

152. F.L.C. G, R.M. E, L.M. DR, F.G. G, F.G. Z, R.B. O, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol [Internet]. 2014;15(1):190. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=25465028&site=ehost-live&scope=site

153. González-Parra E, Aceña Á, Lorenzo Ó, Tarín N, González-Casaus ML, Cristóbal C, et al. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. J Bone Miner Metab. 2016 Sep;34(5):587–98.

154. Gupta V, Ekundayo O, Nemeth ZK, Yang Y, Covic A, Mathe Z, et al. Association between serum osteoprotegerin level and mortality in kidney transplant recipients. Transpl Int Off J Eur Soc Organ Transplant. 2021 Feb;

155. Holden RM, Booth SL, Tuttle A, James PD, Morton AR, Hopman WM, et al. Sequence variation in vitamin K epoxide reductase gene is associated with survival and progressive coronary calcification in chronic kidney disease. Arterioscler Thromb Vasc Biol. 2014;34(7):1591–6.

156. Ikee R, Toyoyama T, Endo T, Tsunoda M, Hashimoto N. Impact of sevelamer hydrochloride on serum magnesium concentrations in hemodialysis patients. Magnes Res. 2016 Apr;29(4):184–90.

157. Jean G, Charra B, Chazot C. Vitamin D Deficiency and Associated Factors in Hemodialysis Patients. J Ren Nutr [Internet]. 2008;18(5):395–9. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=105677388&site=ehost-live&scope=site

158. Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, et al. Association between Very Low PTH Levels and Poor Survival Rates in Haemodialysis Patients: Results from the French ARNOS Cohort. NEPHRON Clin Pract [Internet]. 2011;118(2):c211–6. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L51201905

159. Karsli Ceppioğlu S, Yurdun T, Canbakan M. Assessment of matrix Gla protein, Klotho gene polymorphisms, and oxidative stress in chronic kidney disease. Ren Fail. 2011;33(9):866–74.

160. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29(1):31–5.

161. Kuo T-H, Lin W-H, Chao J-Y, Wu A-B, Tseng C-C, Chang Y-T, et al. Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study. BMC Nephrol. 2019;20(1):266.

162. Liabeuf S, Glorieux G, Lenglet A, Diouf M, Schepers E, Desjardins L, et al. Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? PLoS One. 2013;8(6):e67168.

163. Metry G, Stenvinkel P, Qureshi AR, Carrero JJ, Yilmaz MI, Bárány P, et al. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest [Internet]. 2008;38(11):804–11. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L352548873

164. Nakashima A, Carrero JJ, Qureshi AR, Hirai T, Takasugi N, Ueno T, et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int [Internet]. 2011;22(6):1695–701. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L51056189

165. Nemeth ZK, Mardare NG, Czira ME, Deak G, Kiss I, Mathe Z, et al. Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. Sci Rep. 2015 Oct;5:14518.

166. Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, et al. Elevated Osteoprotegerin Levels Predict Cardiovascular Events in New Hemodialysis Patients. Am J Nephrol. 2009;29(3):257–63.

167. Okamoto T, Tsutaya C, Hatakeyama S, Konishi S, Okita K, Tanaka Y, et al. Low serum butyrylcholinesterase is independently related to low fetuin-A in patients on hemodialysis: a cross-sectional study. Int Urol Nephrol. 2018 Sep;50(9):1713–20.

168. Park S, Lee CJ, Jhee JH, Yun H-R, Kim H, Jung S-Y, et al. Extracellular Fluid Excess Is Significantly Associated With Coronary Artery Calcification in Patients With Chronic Kidney Disease. J Am Heart Assoc. 2018 Jun;7(13).

169. Ramalho J, Petrillo EM, Takeichi APM, Moyses RMA, Titan SM. Calcitriol and FGF-23, but neither PTH nor sclerostin, are associated with calciuria in CKD. Int Urol Nephrol. 2019 Oct;51(10):1823–9.

170. Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol [Internet]. 2011;6(11):2612–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L362887921

171. Schlieper G, Westenfeld R, Krüger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011 Feb;22(2):387–95.

172. Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009;24(10):3157–62.

173. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int [Internet]. 2005;67(6):2383–92. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L41623401

174. Stolic R V, Jovanovic AN, Trajkovic GZ, Kostic MM, Odalovic AM, Sovtic SR, et al. Is low magnesium a clue to arteriovenous fistula complications in hemodialysis? Int Urol Nephrol. 2016;48(5):773–9.

175. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, et al. Circulating Sclerostin and Dickkopf-1 (DKK1) in Predialysis Chronic Kidney Disease (CKD): Relationship with Bone Density and Arterial Stiffness. Calcif Tissue Int. 2012;90(6):473–80.

176. Ulusoy S, Ozkan G, Menteşe A, Yavuz A, Karahan SC, Sümer AU. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level. Clin Biochem. 2012 Nov;45(16–17):1444–9.

177. Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant. 2013;28(12):3024–30.

178. Zhang A-H, Guo W-K, Yu L, Liu W-H. Relationship of Serum Soluble Klotho Levels and Echocardiographic Parameters in Patients on Maintenance Hemodialysis. Kidney Blood Press Res. 2019;44(3):396–404.

179. Zhang Q, Sun L, Jin L. Association Between Angiotensin-Converting Enzyme 2 and Coronary Artery Calcification in Patients on Maintenance Hemodialysis Therapy. Ther Apher Dial. 2015;19(5):466–70.

180. Zou Y, Yang M, Wang J, Cui L, Jiang Z, Ding J, et al. Association of sclerostin with cardiovascular events and mortality in dialysis patients. Ren Fail. 2020 Nov;42(1):282–8.

181. Zou J, Yu Y, Wu P, Lin F-J, Yao Y, Xie Y, et al. Serum phosphorus is related to left ventricular remodeling independent of renal function in hospitalized patients with chronic kidney disease. Int J Cardiol. 2016;221:134–40.

182. Sarmento-Dias M, Santos-Araújo C, Poínhos R, Oliveira B, Sousa M, Simões-Silva L, et al. Phase Angle Predicts Arterial Stiffness and Vascular Calcification in Peritoneal Dialysis Patients. Perit Dial Int J Int Soc Perit Dial. 2017;37(4):451–7.

183. Kiss I, Kiss Z, Ambrus C, Szabó A, Szegedi J, Balla J, et al. Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary--results from a nationwide clinical audit. BMC Nephrol. 2013 Jul;14:155.

184. Marques GL, Hayashi S, Bjällmark A, Larsson M, Riella M, Olandoski M, et al. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5. Sci Rep. 2021 Jan;11(1):2473.

185. Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol. 2012 Dec;7(12):2017–22.

186. Chen H-Y, Chiu Y-L, Chuang Y-F, Hsu S-P, Pai M-F, Lai C-F, et al. Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2010 Oct;56(4):720–7.

187. Schurgers LJ, Barreto D V, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010 Apr;5(4):568–75.

188. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–8.

189. Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, et al. Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients. J Diabetes Complications [Internet]. 2014;28(1):61–5. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=24125760&site=ehost-live&scope=site